Both procalcitonin (PCT) and C-reactive protein (CRP) are biomarkers that are frequently utilized; however, the diagnostic benefits of each of these biomarkers vary. Despite the progress that has been made in critical care medicine, intensive care units (ICUs) continue to face the problem of identifying sepsis at an early stage and providing adequate treatment for it. In this regard, PCT, which is a revolutionary laboratory marker, has lately been demonstrated to be rather beneficial all over the world. PCT is proven to be superior to CRP in terms of accuracy in detection and in assessing the severity of sepsis. This is despite the fact that both markers are unable to differentiate between infectious and noninfectious clinical syndromes.